Sai Life Sciences Ltd (SAILIFE) Q1 FY27 Results Analysis: PAT Jumps 21%, Finance Costs Plunge 38%

Sai Life Sciences Ltd's Q1 FY27 numbers came in soft, with revenue of Rs. 554.29 Cr (+11.66% YoY) and PAT growth of +21.22% YoY. Here's a quick read of what worked, what to watch, and what management said.

Quarter Snapshot

Revenue grew 11.66% YoY but missed management's 15-20% CAGR guidance; EBITDA margin at 26.70% was also below the 28-30% target. PAT grew 21.22% YoY and finance costs declined 38% on debt repayment, but lumpy revenue and QoQ margin compression remain challenges. Capacity expansion catalysts are pending.

Key Investment Insights

Key Positives

• Revenue grew 11.66% YoY to Rs.554.29 Cr.
• EBITDA margin expanded 234 bps YoY to 26.70%.
• PAT grew 21.22% YoY to Rs.73.28 Cr.
• Finance costs declined 38.22% YoY to Rs.7.64 Cr due to debt repayment.
• EBITDA growth (22.39% YoY) outpaced revenue growth (11.66% YoY).
• No exceptional items in Q1FY27; normalized PAT equals reported PAT.

Risk Factors

• Revenue growth of 11.66% YoY is below management's 15-20% CAGR guidance corridor.
• EBITDA margin of 26.70% is below the sustained target band of 28-30%.
• Sequential revenue declined 7.95% QoQ, confirming lumpy revenue pattern.
• QoQ EBITDA margin compressed 262 bps, driven by employee cost share rising 146 bps QoQ.